Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

7.25USD
16 Aug 2018
Change (% chg)

$0.05 (+0.69%)
Prev Close
$7.20
Open
$7.30
Day's High
$7.40
Day's Low
$7.15
Volume
12,525
Avg. Vol
26,932
52-wk High
$11.90
52-wk Low
$3.90

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $136.71
Shares Outstanding(Mil.): 18.60
Dividend: --
Yield (%): --

Financials

  ALDX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.47 -- --
ROI: -72.27 1.78 14.61
ROE: -75.02 3.28 16.33

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

10 May 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL

24 Apr 2018

BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs

* ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES

27 Feb 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.48 +2.05
Novartis AG (NOVN.S) CHF81.72 +0.86
Pfizer Inc. (PFE.N) $41.42 +0.26
AbbVie Inc (ABBV.N) $98.22 +0.77
Amgen, Inc. (AMGN.OQ) $196.44 +1.18
Bristol-Myers Squibb Co (BMY.N) $61.11 +0.85
Bristol-Myers Squibb Co (BMYMP.PK) $999.90 --
UCB SA (UCB.BR) €77.68 --

Earnings vs. Estimates